SCHEMBL2765074

SCHEMBL2765074

Cn1cc(-c2ccc3nnc(Cl)n3n2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
HSD17B10 Q99714 1/20 0.59
FYN P06241 6/20 0.53
MET P08581 9/20 0.52
PDE3B Q13370 3/20 0.52
PDE3A Q14432 3/20 0.52
NQO2 P16083 2/20 0.52
PIP4K2C Q8TBX8 2/20 0.52
ABL1 P00519 1/20 0.52
MAPK8 P45983 1/20 0.52
MAPK10 P53779 1/20 0.52
DYRK1A Q13627 1/20 0.52
MAP3K19 Q56UN5 1/20 0.52
DYRK1B Q9Y463 1/20 0.52
GRK5 P34947 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
PDE2A O00408 1/20 0.47
CHRM2 P08172 1/20 0.47
PDE4A P27815 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509620 0.82 FYN (0.53) FYNMETPDE3BPDE3ANQO2
SCHEMBL16136542 0.80 MET (0.58) FYNMETPDE3BPDE3ANQO2
SCHEMBL18197857 0.79 MET (0.55) FYNMETPDE3BPDE3ANQO2
SCHEMBL18197886 0.79 MET (0.59) FYNMETPDE3BPDE3ANQO2
SCHEMBL2423083 0.78 MET (0.57) FYNMETPDE3BPDE3ANQO2
SCHEMBL13209254 0.78 MET (0.61) FYNMETPDE3BPDE3ANQO2
SCHEMBL3411895 0.73 FYN (0.64) FYNMETPDE3BPDE3ANQO2
SCHEMBL25418160 0.73 MET (0.50) METPDE3BPDE3A
SCHEMBL509206 0.72 MET (0.75) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL2764139 0.72 KDM4E (0.71) KDM4EHSD17B10FYNMETMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321777-B2 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors SANOFI (FR) 2016-04-26 US disclosed
US-20150344484-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS SANOFI-AVENTIS (FR) 2015-12-03 US disclosed
US-9115134-B2 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors SANOFI (FR) 2015-08-25 US disclosed
US-20140005189-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS SANOFI (FR) 2014-01-02 US disclosed
EP-2178881-A2 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS Sanofi-Aventis (FR) 2010-04-28 EP disclosed
WO-2009056692-A2 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344484-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS MET, TPMT, MERTK KDM4E 711/4885HSD17B10 4553/4885FYN 130/4885
US-20140005189-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS MET, TPMT, MERTK KDM4E 711/4885HSD17B10 4553/4885FYN 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.